Abstract 220P
Background
Radiation oral mucositis (radiotherapy-induced oral mucositis, RIOM), as one of the common complications during radiotherapy, is difficult to avoid and predict. Severe RIOM will reduce the quality of life of patients and affect the normal progress of diagnosis and treatment. Early detection and early intervention is very important to reduce the incidence of RIOM, but at present, the sensitivity and specificity of clinical indicators for the occurrence and development of radiation stomatitis are poor, so it is necessary to study further the treatment factors and predictive indicators of radiation stomatitis. It has been found that oral flora are closely related to the progression of radiation oral mucositis.
Methods
27 postoperative patients with oral squamous cell carcinoma were enrolled in the study. The cotton swab samples of oral buccal mucosa before and after radiotherapy were collected. The diversity, species differences and marker species of the oral microbial community were determined by 16 S rRNA sequencing and metagenome sequencing.
Results
Compared with the pre-radiotherapy group, the composition of oral flora in the radiotherapy group and the post-radiotherapy group changed, and the community diversity decreased significantly. The richness of different flora was different. In terms of genera, there was a difference in the richness of Haemophilus during radiotherapy, after radiotherapy and before radiotherapy, and the number of different bacteria was positively correlated with the time of radiotherapy. At the species level, the diversity of Streptococcus pneumoniae and Haemophilus haemolyticus increased significantly after radiotherapy. In terms of functional distribution, based on KEGG and CAZymes database, there were differences in functional distribution between the two groups of oral flora.
Conclusions
Radiotherapy can change the species structure and composition of oral flora and reduce community diversity. Streptococcus pneumoniae and Haemophilus haemolyticus may be related to the occurrence and development of radiation oral mucositis.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
98P - Immuno-related cardiac toxicity: a prospective study applying multiparametric cardiac MRI
Presenter: Agnese Losurdo
Session: Poster Display session
99P - Real-world management of ir-colitis, a Danish 10-year cohort study
Presenter: Soeren Petersen
Session: Poster Display session
101P - Comparison on the effectiveness of multiple single and double immunotherapy treatments on advanced angiosarcoma patients: Meta analysis & systematic review
Presenter: Enzo Marson
Session: Poster Display session
Resources:
Abstract
102P - A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor
Presenter: Saifeng Li
Session: Poster Display session
103P - Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study
Presenter: zhihua wen
Session: Poster Display session
104P - The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) as second- or later-line therapy for metastatic non-small cell lung cancer
Presenter: Hualin Chen
Session: Poster Display session
105P - A retrospective study using machine learning to analyze the effects of VEGFR-TKIs and PD-1 inhibitors as third-line or later treatment in patients with MSS mCRC
Presenter: Shumei Han
Session: Poster Display session
Resources:
Abstract
106P - Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
Presenter: Dimitrios Ziogas
Session: Poster Display session
107P - Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study
Presenter: Yulu Peng
Session: Poster Display session
Resources:
Abstract
108P - Transarterial chemoembolization (TACE) combined with atezolizumab and bevacizumab versus TACE alone in patients with Barcelona Clinic liver cancer stage B unresectable hepatocellular carcinoma: A retrospective, propensity score-matched analysis
Presenter: Hongjie Cai
Session: Poster Display session
Resources:
Abstract